After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer Drugs Fund (CDF). The recommendation from health technology assessment (HTA) agency NICE comes a couple of weeks after Retsevmo (selpercatinib) was cleared for use in …

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer Read More »